Table 1

Clinico-pathological characteristics of patients

Gastric cancer patient

Healthy volunteer

Training

set

Proof-of-principle

test set

(responder)


Number

82

8

34

Age - yr

Median

56

56

48

Interquartile range

(44-63)

(44-58)

(43-57)

Sex - no. (%)

Male

64 (78.0%)

7 (87.5%)

23 (67.6%)

Female

18 (22.0%)

1 (12.5%)

11 (32.4%)

Performance status (PS) - no. (%)

ECOG1 PS 0 or 1

73 (89.0%)

8 (100%)

ECOG PS 2 or 3

9 (11.0%)

0

Histological type - no. (%)

Lauren's intestinal

34 (41.5%)

3 (37.5%)

Lauren's diffuse

48 (58.5%)

5 (62.5%)

Location of primary lesion - no. (%)

Upper 1/3

11 (13.4%)

1 (12.5%)

Middle 1/3

18 (22.0%)

5 (62.5%)

Lower 1/3

43 (52.4%)

1 (12.5%)

Entire stomach

10 (12.2%)

1 (12.5%)

Chemotherapy regimen - no. (%)

Cisplatin/Fluorouracil

80 (97.6%)

8 (100%)

Cisplatin/Capecitabine

2 (2.4%)

0

*Relative dose intensity - %

Median

81.2

76.6

Interquartile range

(75.3-87.3)

(64.7-84.9)

Number of chemotherapy cycles

Median

4

10

Interquartile range

(2-5)

(7-11)

Chemotherapy response (WHO criteria) -no (%)

PR2

16 (24.6%)

6 (100%)

SD3

25 (38.5%)

PD4

24 (36.9%)

Unmeasurable

16

2

Unevaluable

1

Second-line chemotherapy

55 (67.1%)

6 (75.0%)

Median follow-up for survivors

35.5 months

-

Overall survival - mo.

Median

8.2

16

Interquartile range

(6.8-10.5)

(11.3-26.7)

Time to progression - mo.

Median

3.1

8.2

Interquartile range

(2.5-3.9)

(4.3-21.2)


1Eastern Cooperative Oncology Group, 2partial response, 3stable disease, 4progressive disease

*Relative dose intensity

*Mean of relative dose intensities of cisplatin and fluorouracil. Dose intensity is defined as the amount of drug administered per unit of time, expressed as milligrams per square meter per week. Relative dose intensity is defined as the actual dose intensity relative to the planned dose intensity of each drug.

Kim et al. BMC Medical Genomics 2011 4:79   doi:10.1186/1755-8794-4-79

Open Data